Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Gjettum – page 6

616 clinical trials in Gjettum, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Gjettum at a glance
616
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

616 trials in Gjettum

Open in trial search

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Phase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:Odense University Hospital

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Safety and Tolerability of Tenofovir Alafenamide Dose Escalation in Healthy Adults for Epstein‑Barr Virus Infection

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tenofovir Alafenamide
  • Sponsor:Helse Bergen HF

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Lerodalcibep for Heterozygous Familial Hypercholesterolemia in Children and Adolescents 6 to 17 Years Old

Investigational
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Lerodalcibep
  • Sponsor:LIB Therapeutics Inc.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Gjettum

What the registry says about research in the country

01 Gastroenterology Research

Innovative trials focusing on inflammatory bowel diseases, including studies of combination therapies for both Crohn's Disease and Ulcerative Colitis. Research aims to evaluate new treatment approaches using targeted biological agents.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Combination Therapy Assessment

These studies explore dual-therapy approaches to improve clinical outcomes for patients with moderate to severe disease activity.

02 Cardiovascular Studies

Research focusing on prevention and treatment of stroke and cardiac conditions, including innovative approaches for managing atrial fibrillation and evaluating new anticoagulation therapies.

  • Stroke Prevention
  • Atrial Fibrillation Management
  • Thrombolysis Research

Trials aim to improve outcomes in acute ischemic stroke and prevent cardiac complications.

03 Musculoskeletal Medicine

Comprehensive research into orthopedic conditions, including studies on osteoarthritis, carpal tunnel syndrome, and hip fracture treatments.

  • Joint Disease Management
  • Surgical vs. Conservative Treatment
  • Post-fracture Care

Investigations compare different treatment approaches and timing of interventions for optimal patient outcomes.

04 Infectious Disease Research

Studies addressing various infectious conditions including COVID-19 and mpox, evaluating novel therapeutic approaches and treatment strategies.

  • COVID-19 Treatment Trials
  • Mpox Management
  • Antiviral Therapy Assessment

Research focuses on understanding disease progression and testing new therapeutic interventions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.